Search
INCB13739
go.drugbank.com/drugs/DB05064InvestigationalINCB13739 is developed as a new treatment for type 2 diabetes. … It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes
Human C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigational[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalA new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one … Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label].
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexZeranol
go.drugbank.com/drugs/DB11478ExperimentalVet approvedZeranol is a non-steroidal estrogen agonist. It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops. … It is 3-4x more potent as an estrogen agonist than the related compound zearalenone.
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. … Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients.
PBI-1402
go.drugbank.com/drugs/DB05480ExperimentalSince it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.
Mecobalamin
go.drugbank.com/drugs/DB03614ApprovedInvestigationalMixtures: Protect Cardio AF, Folika-TTosedostat
go.drugbank.com/drugs/DB11781InvestigationalIt has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel. … Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase.
Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnBenfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier.
Cobamamide
go.drugbank.com/drugs/DB11191ApprovedNutraceuticalThis drug is available as a nutritional supplement to prevent vitamin B12 deficiency. Vitamin B12 is a collective term for these variously substituted corrinoids. … It is therefore important to treat vitamin B12 deficiency with a combination of MeCbl and AdCbl or hydroxocobalamin or cobalamin [L2054].